Mechanism of Action and Use of Radiomimetic Compounds
Copyright (c) 2022 Deli Gábor
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Absztrakt
Radiomimetic substances are drugs producing similar symptoms in living organisms as ionising radiation does. They constitute a special subgroup of carcinogen, mutagen, teratogen compounds; their common characteristic is to cause DNA breaks and/or to inhibit their repair. Mustard gas and its derivatives – alkylating agents – were the first known group of radiomimetic substances, later, it was observed, that some purine and pyrimidine analogues playing an antimetabolic role show a resembling outcome. Initially mustards were used in warfare, but now their usage for military purpose is prohibited by the Chemical Weapons Convention. Other radiomimetic substances have also become important tools in medicine, as they have been shown to be useful against certain pathogens and tumours. This review is a brief summary about the mechanism of action and the most common applications of alkylating agents and antimetabolites. In the coming second part, the radiomimetic substances of bacterial origin are reviewed from similar perspectives.
Kulcsszavak:
Hogyan kell idézni
Hivatkozások
Andros, Christina C, Ryan A Dubay, Kayleigh D Mitchell, Aaron Chen, Dawn E Holmes and Daniel R Kennedy, ‘A novel application of radiomimetic compounds as antibiotic drugs’. Journal of Pharmacy and Pharmacology 67, no 10 (2015), 1371–1379. Online: https://doi.org/10.1111/jphp.12432
‘Antineoplastic Agents’, in LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
Auerbach, Charlotte, J M Robson and J G Carr, ‘The Chemical Production of Mutations’. Science 105, no 2723 (1947), 243–247. Online: https://doi.org/10.1126/science.105.2723.243
Auerbach, Arleen D, ‘Diagnosis of Fanconi Anemia by Diepoxybutane Analysis’. Current Protocols in Human Genetics 85 (2015), 8.7.1–8.7.17. Online: https://doi.org/10.1002/0471142905.hg0807s85
Avendaño, Carmen and J Carlos Menendez, Medicinal Chemistry of Anticancer Drugs. Amsterdam: Elsevier, 2015.
Azzam, Edouard I, Jean-Paul Jay-Gerin and Debkumar Pain, ‘Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury’. Cancer Letters 327, no 1–2 (2012), 48–60. Online: https://doi.org/10.1016/j.canlet.2011.12.012
Benkhaled, Leila, Mar Xunclà, Maria Rosa Caballín, Leonardo Barrios and Joan-Francesc Barquinero, ‘Induction of complete and incomplete chromosome aberrations by bleomycin in human lymphocytes’. Mutation Research 637, no 1–2 (2008), 134–141. Online: https://doi.org/10.1016/j.mrfmmm.2007.07.013
Boyland, Eric, ‘Azione biologica delle radiazioni e delle sostanze radiomimetiche’. Endeavour 11 (1952), 87–91.
British National Formulary, BNF 69, 69th edition. London: British Medical Association, 2015, 588–592.
Cannan, Wendy J and David S Pederson, ‘Mechanisms and Consequences of Double-strand DNA Break Formation in Chromatin’. Journal of Cellular Physiology 231, no 1 (2016), 3–14. Online: https://doi.org/10.1002/jcp.25048
Chang, Howard H Y, Nicholas R Pannunzio, Noritaka Adachi and Michael R Lieber, ‘Non-homologous DNA end joining and alternative pathways to double-strand break repair’. Nature Reviews Molecular Cell Biology 18 (2017), 495–506. Online: https://doi.org/10.1038/nrm.2017.48
Damia, Giovanna and Maurizio D’Incalci, ‘Mechanisms of resistance to alkylating agents’. Cytotechnology 27, no 1–3 (1998), 165–173. Online: https://doi.org/10.1023/A:1008060720608
Darlington, Cyril D and Peo C Koller, ‘The chemical breakage of chromosomes’. Heredity 1 (1947), 187–221. Online: https://doi.org/10.1038/hdy.1947.13
Deli, Gábor, ‘Cytogenetic Detection Tools for Effects of Ionizing Radiation on Human’. Hadmérnök 13, no 3 (2018), 179–192.
Deli, Gábor, ‘Az ionizáló sugárzás emberi szervezetre gyakorolt hatásának korszerű kimutatási lehetőségei’ [Up-to-date Detection Possibilities of the Effect of Ionizing Radiation on the Human Body]. Honvédorvos 71,
no 1–2 (2019), 31–45. Online: DOI: https://doi.org/10.29068/HO.2019.1-2.31-45
Dustin, Pierre, ‘Some New Aspects of Mitotic Poisoning’. Nature 159 (1947), 794–797. Online: https://doi.org/10.1038/159794a0
Elson, Leslie A, Radiation and Radiomimetic Chemicals. Comparative Physiological Effects. Washington, D.C.: Butterworths, 1963.
Fluorouracil, The American Society of Health-System Pharmacists, 2016.
Ghabili, Kamyar, Paul S Agutter, Mostafa Ghanei, Khalil Ansarin and Mohammadali M Shoja, ‘Mustard gas toxicity: the acute and chronic pathological effects’. Journal of Applied Toxicology 30, no 7 (2010), 627–643. Online: https://doi.org/10.1002/jat.1581
Gilman, Alfred, ‘The initial clinical trial of nitrogen mustard’. The American Journal of Surgery 105, no 5 (1963), 574–578. Online: https://doi.org/10.1016/0002-9610(63)90232-0
Graham, Melanie L, Jody L Janecek, Jessica A Kittredge, Bernhard J Hering, Henk-Jan Schuurman, ‘The Streptozotocin-Induced Diabetic Nude Mouse Model: Differences between Animals from Different Sources’. Comparative Medicine 61, no 4 (2011), 356–360.
Gupta, Ramesh C, Handbook of Toxicology of Chemical Warfare Agents, 2nd edition. Amsterdam: Academic Press, 2015. Online: https://doi.org/10.1016/C2013-0-15402-5
Hoffmann, Wolfgang and Inge Schmitz-Feuerhake, ‘How radiation-specific is the dicentric assay?’ Journal of Exposure Analysis and Environmental Epidemiology 9 (1999), 113–133. Online: https://doi.org/10.1038/sj.jea.7500008
Horstmann, Martin A, Wolf-Achim Hassenpflug, Udo zur Stadt, Gabi Escherich, Gritta Janka and Hartmut Kabisch, ‘Amsacrine combined with etoposide and highdose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children’. Haematologica 90, no 12 (2005), 1701–1703.
Jacob, Leonard S, Pharmacology. The National Series for Independent Studies, 4th edition. Philadelphia: Williams & Wilkins, 1996.
Kashyap, Dharambir, Hardeep Singh Tuli, Katrin Sak, Vivek Kumar Garg, Neelam Goel, Sandeep Punia and Ashun Chaudhary, ‘Role of Reactive Oxygen Species in Cancer Progression’. Current Pharmacology Reports 5 (2019), 79–86. Online: https://doi.org/10.1007/s40495-019-00171-y
Kondo, Natsuko, Akihisa Takahashi, Koji Ono and Takeo Ohnishi, ‘DNA damage induced by alkylating agents and repair pathways’. Journal of Nucleic Acids (2010). Online: https://doi.org/10.4061/2010/543531
Lemaitre, Florian, Françoise Goirand, Manon Launay, Etienne Chatelut, Jean-Christophe Boyer, Alexandre Evrard, Marie-Noelle Paludetto, Romain Guilhaumou, Joseph Ciccolini and Antonin Schmitt, ‘5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer’. Bulletin du Cancer 105, no 9 (2018), 790–803. Online: https://doi.org/10.1016/j.bulcan.2018.06.008
Malhotra, Vikas and Michael C Perry, ‘Classical Chemotherapy: Mechanisms, Toxicities and the Therapeutic Window’. Cancer Biology & Therapy 2, no sup1 (2003), 1–3. Online: https://doi.org/10.4161/cbt.199; DOI: https://doi.org/10.4161/cbt.199
Marshall, Brendan, S Darkin and R K Ralph, ‘Evidence that mAMSA induces topoisomerase action’. FEBS Letters 161, no 1 (1983), 75–78. Online: https://doi.org/10.1016/0014-793(83)80733-9
Mercaptopurine, The American Society of Health-System Pharmacists, 2016.
Moore, Angela Yen, ‘Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders’. Journal of Dermatological Treatment 20, no 6 (2009), 328–335. Online: https://doi.org/10.3109/09546630902789326
National Research Council, Acute Exposure Guideline Levels for Selected Airborne Chemicals, Volume 3. Washington, D.C.: The National Academies Press, 2003.
Organisation for the Prohibition of Chemical Weapons, “Annex 3.” Report of the OPCW on the Implementation of the Convention on the Prohibition of the Development, Production, Stockpiling and Use of Chemical Weapons and on Their Destruction in 2015. OPCW, 2016. Online: https://doi.org/10.1007/978-94-6265-044-2_1
Parker, William B, ‘Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer’. Chemical Reviews 109, no 7 (2009), 2880–2893. Online: https://doi.org/10.1021/cr900028p
Rassnick, Kenneth M, Glenna E Mauldin, Renee Al-Sarraf, G Neal Mauldin, Antony S Moore, Samantha C Mooney, ‘MOPP Chemotherapy for Treatment of Resistant Lymphoma in Dogs: A Retrospective Study of 117 Cases (1989–2000)’. Journal of Veterinary Internal Medicine 16, no 5 (2002), 576–580. Online: https://doi.org/10.1111/j.1939-1676.2002.tb02390.x
Rodriguez, Victorio, Jacqueline S Hart, Emil J Freireich, Gerald P Bodey, Kenneth B McCredie, John P Whitecar, Charles A Coltman, ‘POMP combination chemotherapy of adult acute leukemia’. Cancer 32, no 1 (1973), 69–75. Online: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/1097-0142(197307)32:1%3C69::AID-CNCR2820320109%3E3.0.CO;2-0
Romano, James A, Brian J Lukey and Harry Salem (eds), Chemical Warfare Agents, Chemistry, Pharmacology, Toxicology, and Therapeutics, 2nd edition. Boca Raton: CRC Press, 2007. Online: https://doi.org/10.1201/9781420046625
Rubinstein, Samuel M, Peter C Yang, Andrew J Cowan and Jeremy L Warner, ‘Standardizing Chemotherapy Regimen Nomenclature: A Proposal and Evaluation of the HemOnc and National Cancer Institute Thesaurus Regimen Content’. JCO Clinical Cancer Informatics 4 (2020), 60–70. Online: https://doi.org/10.1200/CCI.19.00122
Sax, Karl and Hally J Sax, ‘Radiomimetic beverages, drugs, and mutagens’. Proceedings of the National Academy of Sciences of the USA 55, no 6 (1966), 1431–1435. Online: https://doi.org/10.1073/pnas.55.6.1431
Sen, Soumitra, Eugenio Erba and Maurizio D’Incalci ‘Synchronisation of cancer cell lines of human origin using methotrexate’. Cytometry 11, no 5 (1990), 595–602. Online: https://doi.org/10.1002/cyto.990110506
Srinivas, Upadhyayula S, Jerzy Dyczkowski, Tim Beißbarth, Jochen Gaedcke, Wael Y Mansour, Kerstin Borgmann and Matthias Dobbelstein, ‘5-Fluorouracil sensitizes colorectal tumor cells towards double stranded DNA breaks by interfering with homologous recombination repair’. Oncotarget 6, no 14 (2015), 12574–12586. Online: https://doi.org/10.18632/oncotarget.3728
Steinritz, Dirk and Horst Thiermann, ‘Sulfur Mustard’, in Critical Care Toxicology, ed. by Jeffrey Brent, Keith Burkhart, Paul Dargan, Benjamin Hatten, Bruno Megarbane, Robert Palmer and Julian White. Cham: Springer, 2017, 2683–2712. Online: https://doi.org/10.1007/978-3-319-17900-1_149
Vazquez, Alexei, Philip M Tedeschi and Joseph R Bertino, ‘Overexpression of the Mitochondrial Folate and Glycine–Serine Pathway: A New Determinant of Methotrexate Selectivity in Tumors’. Cancer Research 73, no 2 (2013), 478–482. Online: https://doi.org/10.1158/0008-5472.CAN-12-3709
Weber, Georg F, ‘DNA Damaging Drugs’, in Molecular Therapies of Cancer. Cham: Springer, 2015, 9–112. Online: https://doi.org/10.1007/978-3-319-13278-5_2
Wróbel, Agnieszka, Karolina Arciszewska, Dawid Maliszewski and Danuta Drozdowska, ‘Trimethoprim and other nonclassical antifolates an excellent templat Agnieszkae for searching modifications of dihydrofolate reductase enzyme inhibitors’. The Journal of Antibiotics 73 (2020), 5–27. Online: https://doi.org/10.1038/s41429-019-0240-6